At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
The company received gross proceeds of approximately US$1.7 million and net proceeds,
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Subscribe To Our Newsletter & Stay Updated
